Skip to main content
. 2018 May 16;8(2):291–301. doi: 10.1007/s13555-018-0240-7

Fig. 3.

Fig. 3

Linear prediction of UAS7 among patients during the first and second cycles of omalizumab administration. Means (dots), 95% confidence interval (whiskers), samples between baseline (week 0) and the end of treatment (week 24) or retreatment (week 20)